The ACP guideline, published in Annals of Internal Medicine, includes three recommendations centered around monotherapy: ...

The Clinical Guidelines Committee of the American College of Physicians (ACP) has released a new clinical guideline on the ...

With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of ...

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...

The American College of Physicians (ACP) has developed new recommendations to prevent episodic migraines in nonpregnant adults in outpatient settings.

Mind+ Neurology is advancing medical research and offering hope to patients living with migraine. Aaron Hart & Kelly Reynolds ...

The American College of Physicians (ACP) has developed new recommendations to prevent episodic migraines in nonpregnant ...

Anti-CGRP antibodies vs onabotulinumtoxinA is not associated with increased cardiovascular disease risk in older patients with migraine, new research suggested.

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.

Migraine is the most common neurological condition in the world, with more than one in seven people suffering from migraines ...

The NICE recommendation of Vyepti as a comparator to other treatments in the CGRP inhibitor class provides another option for people living with episodic or chronic migraine, particularly those ...